Q1 2025 EPS Estimates for Haemonetics Co. (NYSE:HAE) Increased by Analyst

Haemonetics Co. (NYSE:HAE) – Analysts at Zacks Research raised their Q1 2025 EPS estimates for Haemonetics in a research report issued on Tuesday, April 30th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $0.96 per share for the quarter, up from their previous forecast of $0.95. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.06 EPS, Q3 2025 earnings at $1.09 EPS and FY2025 earnings at $4.17 EPS.

A number of other equities analysts have also recently issued reports on the stock. Barrington Research restated an “outperform” rating and set a $105.00 target price on shares of Haemonetics in a research report on Friday, April 12th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th.

Haemonetics Stock Performance

Shares of HAE opened at $92.26 on Thursday. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. The stock has a market cap of $4.69 billion, a P/E ratio of 37.50, a PEG ratio of 2.17 and a beta of 0.34. The company has a 50-day moving average of $81.58 and a two-hundred day moving average of $82.67. Haemonetics has a 12-month low of $70.74 and a 12-month high of $95.26.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.10. The business had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The business’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.85 earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HAE. Norges Bank acquired a new stake in Haemonetics in the fourth quarter valued at $28,591,000. Allspring Global Investments Holdings LLC raised its holdings in Haemonetics by 132.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock valued at $42,930,000 after acquiring an additional 286,897 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in Haemonetics by 27.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock valued at $60,888,000 after acquiring an additional 152,098 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Haemonetics by 50.0% in the third quarter. Victory Capital Management Inc. now owns 357,303 shares of the medical instruments supplier’s stock valued at $32,007,000 after acquiring an additional 119,072 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. acquired a new stake in Haemonetics in the third quarter valued at $9,952,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.